Cite
HARVARD Citation
Duffy, A. et al. (n.d.). Modulation of tumor eIF4E by antisense inhibition: A phase I/II translational clinical trial of ISIS 183750—an antisense oligonucleotide against eIF4E—in combination with irinotecan in solid tumors and irinotecan‐refractory colorectal cancer. International journal of cancer. 139 (7), pp. 1648-1657. [Online].